Literature DB >> 16000507

Discordant rise in galactomannan antigenemia in a patient with resolving Aspergillosis, renal failure, and ongoing hemodialysis.

Chadi M El Saleeby1, Kim J Allison, Katherine M Knapp, Thomas J Walsh, Randall T Hayden.   

Abstract

We describe the case of a patient with improving invasive aspergillosis and paradoxically rising serum galactomannan levels in the presence of chronic renal failure and ongoing hemodialysis. Dialysate tested negative for galactomannan, demonstrating the inability of treatments such as hemodialysis to clear Aspergillus antigen from serum. In patients with renal failure and aspergillosis, rising serum galactomannan levels may not necessarily signify progressive infection.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16000507      PMCID： PMC1169100          DOI： 10.1128/JCM.43.7.3560-3563.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

Authors:  J Maertens; J Verhaegen; K Lagrou; J Van Eldere; M Boogaerts
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

2.  Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients.

Authors:  Johan Maertens; Johan Van Eldere; Jan Verhaegen; Erik Verbeken; Johny Verschakelen; Marc Boogaerts
Journal:  J Infect Dis       Date:  2002-10-08       Impact factor: 5.226

Review 3.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.

Authors:  Monique A S H Mennink-Kersten; J Peter Donnelly; Paul E Verweij
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

4.  Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits.

Authors:  B Dupont; M Huber; S J Kim; J E Bennett
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

5.  Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.

Authors:  Takahiro Fukuda; Michael Boeckh; Rachel A Carter; Brenda M Sandmaier; Michael B Maris; David G Maloney; Paul J Martin; Rainer F Storb; Kieren A Marr
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

6.  Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease.

Authors:  François Boutboul; Corinne Alberti; Thierry Leblanc; Annie Sulahian; Eliane Gluckman; Francis Derouin; Patricia Ribaud
Journal:  Clin Infect Dis       Date:  2002-02-20       Impact factor: 9.079

7.  Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors:  R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction.

Authors:  Thomas J Walsh; Shmuel Shoham; Ruta Petraitiene; Tin Sein; Robert Schaufele; Amy Kelaher; Heidi Murray; Christine Mya-San; John Bacher; Vidmantas Petraitis
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

9.  Receptor-mediated clearance of Aspergillus galactomannan.

Authors:  J E Bennett; M M Friedman; B Dupont
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

Review 10.  Rapid diagnosis of invasive aspergillosis by antigen detection.

Authors:  L J Wheat
Journal:  Transpl Infect Dis       Date:  2003-12       Impact factor: 2.228
View more
  5 in total

Review 1.  Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay.

Authors:  L J Wheat; T J Walsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

2.  Challenges with Utilizing the 1,3-Beta-d-Glucan and Galactomannan Assays To Diagnose Invasive Mold Infections in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Sean X Zhang
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

Review 3.  Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age.

Authors:  Toine Mercier; Ellen Guldentops; Katrien Lagrou; Johan Maertens
Journal:  Front Microbiol       Date:  2018-04-04       Impact factor: 5.640

Review 4.  Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis.

Authors:  Valério R Aquino; Luciano Z Goldani; Alesssandro C Pasqualotto
Journal:  Mycopathologia       Date:  2007-04-05       Impact factor: 3.785

5.  Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis.

Authors:  Louis Yi Ann Chai; Bart Jan Kullberg; Arul Earnest; Elizabeth M Johnson; Steven Teerenstra; Alieke G Vonk; Haran T Schlamm; Raoul Herbrecht; Mihai G Netea; Peter F Troke
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.